| Jun 28 |
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
|
| Jun 21 |
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
|
| Jun 11 |
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
|
| Jun 4 |
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
|
| May 31 |
Is NurExone Biologic (CVE:NRX) In A Good Position To Deliver On Growth Plans?
|
| May 29 |
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
|
| May 17 |
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
|
